Mark Moody, Ph.D. of Activate will present “Nanomedicine Formulations for Delivery of TLR Agonist Drug Combinations” at the May 9-11 STING&TLR-Targeting Therapies conference in Boston.

  • Explore how Activate has developed lipogel nanoparticles (LgNPs) that co-package combinations of TLR agonists to provide sustained delivery of these drugs to the tumor, while reducing systemic exposure and associated toxicity
  • Assess how these LgNPs are phagocytized by macrophages and dendritic cells, delivering TLR agonists to the endosomes where TLR targets reside
  • Analyze how TLR-based combination therapies have been shown to be more effective than monotherapies, and how Activate’s LgNP-based therapies have the potential to improve patient outcomes